ERBB2 and cancer: BC is a heterogeneous disease classified into subtypes based on receptor expression: hormone-dependent cancers (ER+/PR+) in 70 % of cases, HER2-overexpressing cancers in 15 % of cases, and triple-negative breast cancer (TNBC) in 15 % of cases [2].